| Literature DB >> 28629160 |
Huimin Shi1, Li Yu2, Yun Shi3, Jiaojiao Lu4, He Teng5, Yifa Zhou6, Lin Sun7.
Abstract
A rhamnogalacturonan I domain, named RG-I-3A, was prepared from ginseng pectin by pectinase digestion and chromatography separation. Monosaccharide composition analysis revealed that it was mainly composed of galacturonic acid, rhamnose, galactose, and arabinose in a molar ratio of 32.5:11.2:31.9:16.5, with a molecular weight of 50 kDa. Partial acid hydrolysis, monoclonal antibody detection, and NMR spectra analysis suggested RG-I-3A was composed of →4)-α-GalpA-(1→2)-α-Rhap-(1→disaccharide repeating units as backbone, with β-1,4-galactan, α-1,5-arabinan, AG-I, and AG-II side chains substituted via the O-4 of Rhap. Galectin-3-mediated hemagglutination and biolayer interferometry assay indicated that RG-I-3A had inhibitory activity on galectin-3. These findings suggest the potential use of this ginseng RG-I domain as a galectin-3 inhibitor in drug development applications.Entities:
Keywords: galectin-3; ginseng; pectin; rhamnogalacturonan I
Mesh:
Substances:
Year: 2017 PMID: 28629160 PMCID: PMC6152741 DOI: 10.3390/molecules22061016
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Fractionation and purification protocol of RG-I-3A from ginseng polysaccharides.
Molecular weights and sugar compositions of RG-I-3A fractions following acid hydrolysis.
| Fraction | Mw (kDa) | Sugar Compositions (mol %) | ||||||
|---|---|---|---|---|---|---|---|---|
| GalA | Rha | Gal | Ara | GlcA | Glc | Man | ||
| RG-I-3A | 50.0 ± 1.05 | 32.5±0.76 | 11.2 ± 0.38 | 31.9 ± 0.66 | 16.5 ± 0.35 | 3.0 ± 0.15 | 1.9 ± 0.30 | 2.1 ± 0.22 |
| RG-I-3A-0.5 | 43.0 ± 0.96 | 33.2 ± 0.55 | 30.3 ± 0.47 | 21.6 ± 0.54 | 8.0 ± 0.30 | 2.1 ± 0.21 | 2.6 ± 0.26 | 1.6 ± 0.25 |
| RG-I-3A-2 | 21.5 ± 0.88 | 37.8 ± 0.45 | 37.2 ± 0.45 | 20.3 ± 0.50 | --- | 2.4 ± 0.17 | 1.7 ± 0.19 | 1.7 ± 0.20 |
| RG-I-3A-4 | 7.2 ± 0.80 | 40.2 ± 0.48 | 39.6 ± 0.51 | 14.8 ± 0.45 | --- | 2.5 ± 0.17 | 1.9 ± 0.15 | 0.9 ± 0.15 |
| RG-I-3A-6 | 6.3 ± 0.55 | 41.2 ± 0.52 | 40.1 ± 0.36 | 13.3 ± 0.37 | --- | 2.9 ± 0.22 | 2.2 ± 0.23 | 0.3 ± 0.09 |
| RG-I-3A-16 | 6.0 ± 0.60 | 45.6 ± 0.61 | 44.8 ± 0.44 | 5.7 ± 0.32 | --- | 1.9 ± 0.15 | --- | 1.9 ± 0.18 |
Cell wall glycan-directed monoclonal antibodies.
| Pectin | Antibody | Antigen Epitope | Reference |
|---|---|---|---|
| HG a | LM19 | Partially Me-HG/de-esterified HG | [ |
| HG a | LM20 | Partially Me-HG | [ |
| RG-I b | LM5 | (1→4)-β- | [ |
| RG-I b | LM6 | Linear (1→5)-α-L-arabinan (~five (1→5)-α-Ara) | [ |
| AGP c | LM14 | AGP glycan (AG-II) | [ |
| AGP c | JIM13 | AGP glycan (AG-II) | [ |
| AGP c | JIM16 | AGP glycan (AG-II) | [ |
a HG: homogalacturonan; b RG-I: rhamnogalacturonan I; c AGP: arabinogalactan-protein.
Figure 2Changes in the binding of monoclonal antibodies to the RG-I-3A-related fractions. The values indicate the means of triplicate experiments. Horizontal dotted lines indicate background signal was lower than 0.1.
Figure 313C-NMR spectrum of (A) RG-I-3A, (B) RG-I-3A-0.5, (C) RG-I-3A-2, and (D) RG-I-3A-16.
Figure 41H-NMR spectrum of (A) RG-I-3A, (B) RG-I-3A-0.5, (C) RG-I-3A-2, and (D) RG-I-3A-16.
13C and 1H-NMR spectral assignments of RG-I-3A, RG-I-3A-0.5, RG-I-3A-2, and RG-I-3A-16.
| Fraction | Sugar Residues | Chemical Shifts, δ (ppm) | |||||
|---|---|---|---|---|---|---|---|
| C-1/H-1 | C-2/H-2 | C-3/H-3 | C-4/H-4 | C-5/H-5 | C-6/H-6 | ||
| RG-I-3A | →4)-α-Gal | 97.51/5.02 | 66.78/3.87 | 68.26/3.83 | 76.30/4.34 | 70.05/4.94 | 172.44/-- |
| →2)-α-Rha | 96.44/5.17 | 75.63/4.06 | 69.05/3.77 | 69.65/3.33 | 67.57/3.53 | 15.50/1.18 | |
| →2,4)-α-Rha | 96.44/5.17 | 75.63/4.06 | 69.05/3.75 | 76.10/3.54 | 67.57/3.55 | 15.72/1.24 | |
| t-β-Gal | 102.26/4.54 | 70.84/3.45 | 73.39/3.61 | 67.99/4.09 | 74.59/3.65 | 59.85/3.73 | |
| →4)-β-Gal | 102.59/4.54 | 71.72/3.45 | 72.73/3.61 | 75.47/4.14 | 73.39/3.70 | 59.85/3.73 | |
| →3)-β-Gal | 103.22/4.57 | 71.74/3.45 | 79.36/-- | 67.99/4.09 | 74.59/3.65 | 59.94/3.73 | |
| →6)-β-Gal | 103.22/4.55 | 71.74/3.45 | 73.39/3.61 | 67.99/4.09 | 74.59/3.66 | 67.17/4.14 | |
| →3,6)-β-Gal | 102.37/4.57 | 71.74/3.45 | 79.36/-- | 67.99/4.09 | 74.59/3.66 | 67.17/4.14 | |
| →5)-α-Ara | 106.45/5.05 | 81.06/4.22 | 79.75/-- | 81.67/4.14 | 65.83/3.88 | --/-- | |
| →3,5)-α-Ara | 106.36/5.05 | 79.85/4.22 | 82.90/-- | 80.13/4.14 | 65.12/3.88 | --/-- | |
| t-α-Ara | 108.26/5.08 | 81.06/4.22 | 79.75/-- | 81.27/4.14 | 60.13/3.61 | --/-- | |
| RG-I-3A-0.5 | →4)-α-Gal | 97.96/4.96 | 66.50/3.84 | 68.96/3.83 | 76.66/4.38 | 70.47/4.93 | 171.45/-- |
| →2)-α-Rha | 96.61/5.14 | 75.30/4.09 | 69.62/3.79 | 70.13/3.36 | 68.24/3.58 | 15.30/1.18 | |
| →2,4)-α-Rha | 96.86/5.14 | 75.30/4.09 | 69.61/3.78 | 76.05/3.54 | 68.24/3.59 | 15.54/1.25 | |
| t-β-Gal | 102.28/4.54 | 70.25/3.46 | 73.28/3.65 | 67.06/4.00 | 73.35/3.68 | 59.76/3.78 | |
| →6)-β-Gal | 103.12/4.55 | 69.86/3.46 | 73.28/3.65 | 67.06/4.00 | 73.35/3.93 | 67.06/4.14 | |
| →3,6)-β-Gal | 102.54/4.57 | 69.86/3.47 | 80.02/-- | 67.06/4.00 | 73.35/3.93 | 67.06/4.14 | |
| RG-I-3A-2 | →4)-α-Gal | 98.08/4.93 | 66.65/3.85 | 68.38/3.80 | 76.78/4.38 | 70.62/4.81 | 171.61/-- |
| →2)-α-Rha | 96.74/5.15 | 75.42/4.06 | 69.11/3.78 | 70.62/3.31 | 68.18/3.59 | 15.43/1.22 | |
| →2,4)-α-Rha | 96.99/5.15 | 75.42/4.06 | 69.11/3.78 | 76.22/3.55 | 68.18/3.61 | 15.68/1.27 | |
| t-β-Gal | 102.41/4.53 | 70.13/3.53 | 73.75/3.66 | 67.54/4.00 | 73.42/3.68 | 59.89/3.76 | |
| →6)-β-Gal | 103.25/4.55 | 69.65/3.53 | 73.75/3.66 | 67.54/4.00 | 73.42/3.94 | 67.75/4.11 | |
| →3,6)-β-Gal | 102.64/4.56 | 69.65/3.55 | --/-- | 67.54/4.02 | 73.42/3.94 | 67.75/4.11 | |
| RG-I-3A-16 | →4)-α-Gal | 98.00/4.96 | 66.65/3.81 | 68.31/3.77 | 76.70/4.38 | 70.62/4.88 | 171.86/-- |
| →2)-α-Rha | 96.69/5.14 | 75.37/4.06 | 68.47/3.69 | 69.24/3.31 | 68.21/3.59 | 15.44/1.22 | |
Figure 5Biolayer interferometry analysis of the binding affinity of RG-I-3A to galectin-3. Association and dissociation curves are presented, and KD values were analyzed using the Fortebio Data Analysis Software 7.0. RG-I-3A concentrations (from top to bottom): 1.6, 0.8, 0.4, 0.2, 0.1 μM.